**Editorial**

199 HIV/AIDS and the road to Rome  
R Schijff and others

200 Warning: a hard habit to break  
K H Morgan

200 Cardiovascular disease in women—often silent and fatal

**Comment**

201 Rilpivirine: a step forward in tailored HIV treatment  
J S Mclane

203 The concurrency debate: time to put it to rest  
N J Padman, S Maman

204 Test and treat in HIV: success could depend on rapid detection  
T Cohan, E J Cobbett

206 Antiretrovirals for HIV prevention: translating promise into praxis  
K H Morgan

208 Treatment as prevention—a double hat-trick  
J S Mclane

209 Treatment 2.0: catalysing the next phase of scale-up  
G Himbert, B Schwartlander

211 Let there be light: The Wakley Prize 2011  
N Boyce and others

212 Offline: A seeker of silences  
R Horton

**World Report**

213 Quest for an effective AIDS vaccine takes a new tack  
J Maurice

215 Battles with donors cloud Malawi’s HIV prevention plan  
J Donnelly

**Perspectives**

217 Building the momentum to prevent HIV in MSM  
T J Coates

218 Bertrand Audoin: promoting a global strategy for IAS  
U Samarasakera

219 Kamarl and Arash Alaei: championing HIV/AIDS initiatives in Iran  
P Shetty

220 Should health professionals play the global health security card?  
S Elbe

**Obituary**

222 Peter John Iliff  
G Watts

**Correspondence**

223 Response to Correspondence on Great Ormond Street Hospital  
K Holt

224 Great Ormond Street Hospital and its management team  
T Blackstone and others

225 Radiology service at Great Ormond Street Hospital  
K Chang and others

228 HPTN 052 and the future of HIV treatment and prevention  
W Cates, H Epstien, M Morris, A Seale and others

226 A strategic revolution in HIV and global health  
R England

226 Body-mass index, abdominal adiposity, and cardiovascular risk  
S Yusuf, S Anand, F B Gopalan and others; D Warnmer and others

228 Department of Error

**Articles**

229 Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial  
J C Cohen and others

238 Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial  
J-M Molina and others

247 Effect of concurrent sexual partnerships on rate of new HIV infections in a high-prevalence, rural South African population: a cohort study  
F Tanser and others

256 The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilingwe, Malawi: a modelling study  
K A Powers and others

**Review**

269 HIV prevention transformed: the new prevention research agenda  
N S Padan and others

**Case Report**

288 Uncommon reaction to a common prescription  
K Khodakaram, N Ilmano

**Perspective**

279 Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women  
S S Abdool Karim and others

282 Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach  
E J Schouten and others

285 Can further placebo-controlled trials of antiretroviral drugs to prevent sexual transmission of HIV be justified?  
J Eflin and others

**Viewpoint**

285 Should health professionals play the global health security card?  
S Elbe